Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| INTUITIVE SURGICAL INCISRG · Entity 2878 | Director | April 23, 2019 | April 25, 2019 |
| MANNKIND CORPMNKD · Entity 4792 | Director | May 20, 2026 | May 23, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
INTUITIVE SURGICAL INC
Report date April 23, 2019 · Filed April 25, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 4,751 |
Ending reported balance
After 2019-04-23 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2019-04-23 · Exercise / conversion · Acquired 996 · Balance 5,747 F1: This transaction took place in accordance with a Trading Plan that complies with SEC Rule 10b5-1 and expires on August 6, 2019. Row 2 · 2019-04-23 · Sale · Disposed 996 · Balance 4,751 F1: This transaction took place in accordance with a Trading Plan that complies with SEC Rule 10b5-1 and expires on August 6, 2019. |
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $462.71 · Expires 2028-04-19 | Direct | 0 |
Reported balance
After 2019-04-23 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2019-04-23 · Exercise / conversion · Disposed 996 · Balance 0 F1: This transaction took place in accordance with a Trading Plan that complies with SEC Rule 10b5-1 and expires on August 6, 2019. F2: Non-statutory stock option granted pursuant to the Non-Employee Directors' Stock Option Plan. Option shall vest 100% one year after the date of grant or at the next Shareholders Meeting, whichever should take place first, provided that vesting will cease on termination of the Directors service to the Company. |
Filing footnotes · ownership attribution and instrument terms
F1: This transaction took place in accordance with a Trading Plan that complies with SEC Rule 10b5-1 and expires on August 6, 2019.
F2: Non-statutory stock option granted pursuant to the Non-Employee Directors' Stock Option Plan. Option shall vest 100% one year after the date of grant or at the next Shareholders Meeting, whichever should take place first, provided that vesting will cease on termination of the Directors service to the Company.
MANNKIND CORP
Report date May 20, 2026 · Filed May 23, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 82,781 |
Reported balance
After 2026-05-20 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-05-20 · Grant · Acquired 82,781 · Balance 82,781 F1: Each restricted stock unit represents a contingent right to receive one share of MNKD common stock. F2: Restricted stock unit vested on May 20, 2026, but the shares will not be delivered until there is a separation of service from the board of directors of MannKind Corporation. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents a contingent right to receive one share of MNKD common stock.
F2: Restricted stock unit vested on May 20, 2026, but the shares will not be delivered until there is a separation of service from the board of directors of MannKind Corporation.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
CELGENE CORP /DE/
Report date November 20, 2019 · Filed November 22, 2019
Section 16 reporting ended · disclosed 2019-11-22. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectFamily Trust | 0 |
Reported balance
After 2019-11-20 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2019-11-20 · Disposition to issuer · Disposed 19,847 · Balance 0 F1: Reflects disposition in connection with the Agreement and Plan of Merger (the "Merger Agreement") dated January 2, 2019, by and among Celgene Corporation ("Celgene"), Bristol-Myers Squibb Company ("BMS"), and Burgundy Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BMS ("Merger Sub"), pursuant to which Merger Sub will merge with and into Celgene, with Celgene surviving as a direct wholly owned subsidiary of BMS and upon the effective time of such merger (the "Effective Time"), each share of Celgene common stock was converted into the right to receive (i) $50.00 in cash, (ii) one share of BMS common stock, and (iii) one contingent value right ("CVR") issued by BMS subject to and in accordance with the CVR agreement, dated November 20, 2019, by and between BMS and the Equiniti Trust Company. F2: The reporting person disclaims beneficial ownership of these securities and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $59.06 · Expires 2023-06-12 | Direct | 0 |
Reported balance
After 2019-11-20 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2019-11-20 · Disposition to issuer · Disposed 3,600 · Balance 0 F4: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F3: This option was fully exercisable. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $88.50 · Expires 2024-07-01 | Direct | 0 |
Reported balance
After 2019-11-20 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2019-11-20 · Disposition to issuer · Disposed 20,700 · Balance 0 F4: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F3: This option was fully exercisable. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $112.16 · Expires 2025-06-17 | Direct | 0 |
Reported balance
After 2019-11-20 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2019-11-20 · Disposition to issuer · Disposed 10,000 · Balance 0 F4: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F3: This option was fully exercisable. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $99.98 · Expires 2026-06-15 | Direct | 0 |
Reported balance
After 2019-11-20 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2019-11-20 · Disposition to issuer · Disposed 11,000 · Balance 0 F4: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F3: This option was fully exercisable. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $121.04 · Expires 2027-06-14 | Direct | 0 |
Reported balance
After 2019-11-20 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2019-11-20 · Disposition to issuer · Disposed 10,500 · Balance 0 F4: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F3: This option was fully exercisable. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $77.38 · Expires 2028-06-13 | Direct | 0 |
Reported balance
After 2019-11-20 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2019-11-20 · Disposition to issuer · Disposed 13,266 · Balance 0 F4: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F3: This option was fully exercisable. |
| Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2019-11-20 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2019-11-20 · Disposition to issuer · Disposed 300 · Balance 0 F5: Each restricted stock unit represents a contingent right to receive one share of Celgene common stock. F6: Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement and became vested. The converted restricted stock units will be settled as promptly as practicable following the Effective Time. |
| Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2019-11-20 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2019-11-20 · Disposition to issuer · Disposed 970 · Balance 0 F5: Each restricted stock unit represents a contingent right to receive one share of Celgene common stock. F6: Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement and became vested. The converted restricted stock units will be settled as promptly as practicable following the Effective Time. |
| Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2019-11-20 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2019-11-20 · Disposition to issuer · Disposed 4,756 · Balance 0 F5: Each restricted stock unit represents a contingent right to receive one share of Celgene common stock. F6: Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement and became vested. The converted restricted stock units will be settled as promptly as practicable following the Effective Time. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects disposition in connection with the Agreement and Plan of Merger (the "Merger Agreement") dated January 2, 2019, by and among Celgene Corporation ("Celgene"), Bristol-Myers Squibb Company ("BMS"), and Burgundy Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BMS ("Merger Sub"), pursuant to which Merger Sub will merge with and into Celgene, with Celgene surviving as a direct wholly owned subsidiary of BMS and upon the effective time of such merger (the "Effective Time"), each share of Celgene common stock was converted into the right to receive (i) $50.00 in cash, (ii) one share of BMS common stock, and (iii) one contingent value right ("CVR") issued by BMS subject to and in accordance with the CVR agreement, dated November 20, 2019, by and between BMS and the Equiniti Trust Company.
F2: The reporting person disclaims beneficial ownership of these securities and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.
F3: This option was fully exercisable.
F4: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement.
F5: Each restricted stock unit represents a contingent right to receive one share of Celgene common stock.
F6: Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement and became vested. The converted restricted stock units will be settled as promptly as practicable following the Effective Time.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 20, 2026 Filed May 23, 2026 01:10 UTC | MANNKIND CORP MNKD · Entity 4792 | GrantRestricted Stock Unit · Derivative | 82,781 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-237456 · ownership.xml · derivative · entry 1 Friedman Michael A · CIK 0001298083 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 82,781 Underlying: Common Stock, $0.01 Par Value · 82,781 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of MNKD common stock. F2 · kind: Restricted stock unit vested on May 20, 2026, but the shares will not be delivered until there is a separation of service from the board of directors of MannKind Corporation. F2 · derivative.exercise_date: Restricted stock unit vested on May 20, 2026, but the shares will not be delivered until there is a separation of service from the board of directors of MannKind Corporation. F2 · derivative.expiration_date: Restricted stock unit vested on May 20, 2026, but the shares will not be delivered until there is a separation of service from the board of directors of MannKind Corporation. Read SEC document |
| May 14, 2025 Filed May 16, 2025 22:07 UTC | MANNKIND CORP MNKD · Entity 4792 | GrantRestricted Stock Unit · Derivative | 52,854 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-073777 · ownership.xml · derivative · entry 1 Friedman Michael A · CIK 0001298083 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 52,854 Underlying: Common Stock, $0.01 Par Value · 52,854 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of MNKD common stock. F2 · kind: Restricted stock unit vested on May 14, 2025, but the shares will not be delivered until there is a separation of service from the board of directors of MannKind Corporation. F2 · derivative.exercise_date: Restricted stock unit vested on May 14, 2025, but the shares will not be delivered until there is a separation of service from the board of directors of MannKind Corporation. F2 · derivative.expiration_date: Restricted stock unit vested on May 14, 2025, but the shares will not be delivered until there is a separation of service from the board of directors of MannKind Corporation. Read SEC document |
| May 15, 2024 Filed May 18, 2024 01:31 UTC | MANNKIND CORP MNKD · Entity 4792 | GrantRestricted Stock Unit · Derivative | 35,047 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-062083 · ownership.xml · derivative · entry 1 Friedman Michael A · CIK 0001298083 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,047 Underlying: Common Stock, $.01 Par Value · 35,047 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of MNKD common stock. F2 · kind: Restricted stock unit vested on May 15, 2024, but the shares will not be delivered until there is a separation of service from the board of directors of MannKind Corporation. F2 · derivative.exercise_date: Restricted stock unit vested on May 15, 2024, but the shares will not be delivered until there is a separation of service from the board of directors of MannKind Corporation. F2 · derivative.expiration_date: Restricted stock unit vested on May 15, 2024, but the shares will not be delivered until there is a separation of service from the board of directors of MannKind Corporation. Read SEC document |
| May 25, 2023 Filed May 27, 2023 01:00 UTC | MANNKIND CORP MNKD · Entity 4792 | GrantRestricted Stock Unit · Derivative | 35,545 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-032720 · doc4.xml · derivative · entry 1 Friedman Michael A · CIK 0001298083 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,545 Underlying: Common Stock · 35,545 shares Expires 2033-05-25 F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of MNKD common stock. F2 · derivative.exercise_date: Restricted stock unit vested on May 25, 2023, but the shares will not be delivered until there is a separation of service from the board of directors of MannKind Corporation. Read SEC document |
| May 10, 2022 Filed May 13, 2022 00:00 UTC | MANNKIND CORP MNKD · Entity 4792 | GrantRestricted Stock Unit · Derivative | 45,045 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-028669 · doc4.xml · derivative · entry 1 Friedman Michael A · CIK 0001298083 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,045 Underlying: Common Stock · 45,045 shares Expires 2032-05-10 F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of MNKD common stock. F2 · derivative.exercise_date: Annual Equity Award: Restricted stock unit shall vest immediately, but the shares shall not be delivered until there is a separation of service, such as through resignation or retirement from the Board or his or her death. Read SEC document |
| May 20, 2021 Filed May 21, 2021 01:00 UTC | MANNKIND CORP MNKD · Entity 4792 | GrantRestricted Stock Unit · Derivative | 33,860 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-034724 · doc4.xml · derivative · entry 1 Friedman Michael A · CIK 0001298083 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,860 Underlying: Common Stock · 33,860 shares Expires 2031-05-20 F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of MNKD common stock. F2 · derivative.exercise_date: Annual Equity Award: Restricted stock unit shall vest immediately, but the shares shall not be delivered until there is a separation of service, such as through resignation or retirement from the Board or his or her death. Read SEC document |
| May 21, 2020 Filed May 27, 2020 00:17 UTC | MANNKIND CORP MNKD · Entity 4792 | GrantRestricted Stock Unit · Derivative | 88,235 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-032194 · doc4.xml · derivative · entry 1 Friedman Michael A · CIK 0001298083 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,235 Underlying: Common Stock · 88,235 shares Expires 2030-05-21 F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of MNKD common stock. F2 · derivative.exercise_date: Annual Equity Award: Restricted stock unit shall vest immediately, but the shares shall not be delivered until there is a separation of service, such as through resignation or retirement from the Board or his or her death. Read SEC document |
| November 20, 2019 Filed Nov 22, 2019 07:30 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | Disposition to issuerRestricted Stock Unit · Derivative | 4,756 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001415889-19-001369 · form4-11222019_071137.xml · derivative · entry 10 Friedman Michael A · CIK 0001298083 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,756 shares Expires not disclosed F5 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Celgene common stock. F6 · price: Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement and became vested. The converted restricted stock units will be settled as promptly as practicable following the Effective Time. F6 · derivative.exercise_date: Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement and became vested. The converted restricted stock units will be settled as promptly as practicable following the Effective Time. F6 · derivative.expiration_date: Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement and became vested. The converted restricted stock units will be settled as promptly as practicable following the Effective Time. Read SEC document |
| November 20, 2019 Filed Nov 22, 2019 07:30 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | Disposition to issuerRestricted Stock Unit · Derivative | 970 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001415889-19-001369 · form4-11222019_071137.xml · derivative · entry 9 Friedman Michael A · CIK 0001298083 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 970 shares Expires not disclosed F5 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Celgene common stock. F6 · price: Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement and became vested. The converted restricted stock units will be settled as promptly as practicable following the Effective Time. F6 · derivative.exercise_date: Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement and became vested. The converted restricted stock units will be settled as promptly as practicable following the Effective Time. F6 · derivative.expiration_date: Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement and became vested. The converted restricted stock units will be settled as promptly as practicable following the Effective Time. Read SEC document |
| November 20, 2019 Filed Nov 22, 2019 07:30 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | Disposition to issuerRestricted Stock Unit · Derivative | 300 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001415889-19-001369 · form4-11222019_071137.xml · derivative · entry 8 Friedman Michael A · CIK 0001298083 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 300 shares Expires not disclosed F5 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Celgene common stock. F6 · price: Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement and became vested. The converted restricted stock units will be settled as promptly as practicable following the Effective Time. F6 · derivative.exercise_date: Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement and became vested. The converted restricted stock units will be settled as promptly as practicable following the Effective Time. F6 · derivative.expiration_date: Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement and became vested. The converted restricted stock units will be settled as promptly as practicable following the Effective Time. Read SEC document |
| November 20, 2019 Filed Nov 22, 2019 07:30 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | Disposition to issuerStock Option (right to buy) · Derivative | 13,266 | $0.00 Strike: $77.38 | $0.00 |
DisclosureSEC source: 0001415889-19-001369 · form4-11222019_071137.xml · derivative · entry 7 Friedman Michael A · CIK 0001298083 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 13,266 shares Expires 2028-06-13 F4 · price: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F3 · derivative.exercise_date: This option was fully exercisable. F4 · derivative.exercise_date: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. Read SEC document |
| November 20, 2019 Filed Nov 22, 2019 07:30 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | Disposition to issuerStock Option (right to buy) · Derivative | 10,500 | $0.00 Strike: $121.04 | $0.00 |
DisclosureSEC source: 0001415889-19-001369 · form4-11222019_071137.xml · derivative · entry 6 Friedman Michael A · CIK 0001298083 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,500 shares Expires 2027-06-14 F4 · price: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F3 · derivative.exercise_date: This option was fully exercisable. F4 · derivative.exercise_date: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. Read SEC document |
| November 20, 2019 Filed Nov 22, 2019 07:30 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | Disposition to issuerStock Option (right to buy) · Derivative | 11,000 | $0.00 Strike: $99.98 | $0.00 |
DisclosureSEC source: 0001415889-19-001369 · form4-11222019_071137.xml · derivative · entry 5 Friedman Michael A · CIK 0001298083 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 11,000 shares Expires 2026-06-15 F4 · price: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F3 · derivative.exercise_date: This option was fully exercisable. F4 · derivative.exercise_date: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. Read SEC document |
| November 20, 2019 Filed Nov 22, 2019 07:30 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | Disposition to issuerStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $112.16 | $0.00 |
DisclosureSEC source: 0001415889-19-001369 · form4-11222019_071137.xml · derivative · entry 4 Friedman Michael A · CIK 0001298083 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2025-06-17 F4 · price: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F3 · derivative.exercise_date: This option was fully exercisable. F4 · derivative.exercise_date: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. Read SEC document |
| November 20, 2019 Filed Nov 22, 2019 07:30 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | Disposition to issuerStock Option (right to buy) · Derivative | 20,700 | $0.00 Strike: $88.50 | $0.00 |
DisclosureSEC source: 0001415889-19-001369 · form4-11222019_071137.xml · derivative · entry 3 Friedman Michael A · CIK 0001298083 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,700 shares Expires 2024-07-01 F4 · price: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F3 · derivative.exercise_date: This option was fully exercisable. F4 · derivative.exercise_date: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. Read SEC document |
| November 20, 2019 Filed Nov 22, 2019 07:30 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | Disposition to issuerStock Option (right to buy) · Derivative | 3,600 | $0.00 Strike: $59.06 | $0.00 |
DisclosureSEC source: 0001415889-19-001369 · form4-11222019_071137.xml · derivative · entry 2 Friedman Michael A · CIK 0001298083 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,600 shares Expires 2023-06-12 F4 · price: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F3 · derivative.exercise_date: This option was fully exercisable. F4 · derivative.exercise_date: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. Read SEC document |
| November 20, 2019 Filed Nov 22, 2019 07:30 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | Disposition to issuerCommon Stock | 19,847 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-19-001369 · form4-11222019_071137.xml · nonDerivative · entry 1 Friedman Michael A · CIK 0001298083 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Family Trust Disclosed balance after: 0 F1 · price: Reflects disposition in connection with the Agreement and Plan of Merger (the "Merger Agreement") dated January 2, 2019, by and among Celgene Corporation ("Celgene"), Bristol-Myers Squibb Company ("BMS"), and Burgundy Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BMS ("Merger Sub"), pursuant to which Merger Sub will merge with and into Celgene, with Celgene surviving as a direct wholly owned subsidiary of BMS and upon the effective time of such merger (the "Effective Time"), each share of Celgene common stock was converted into the right to receive (i) $50.00 in cash, (ii) one share of BMS common stock, and (iii) one contingent value right ("CVR") issued by BMS subject to and in accordance with the CVR agreement, dated November 20, 2019, by and between BMS and the Equiniti Trust Company. F2 · ownership.nature: The reporting person disclaims beneficial ownership of these securities and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose. Read SEC document |
| June 15, 2019 Filed Jun 17, 2019 16:00 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | Exercise / conversionRestricted Stock Unit · Derivative | 375 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-19-000729 · form4-06172019_040620.xml · derivative · entry 7 Friedman Michael A · CIK 0001298083 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 375 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: The remaining one-third of the restricted stock units granted to the reporting person on June 15, 2016 vested and settled for shares of the Company's common stock. F8 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. F10 · price: The restricted stock units were issued pursuant to the Company's 2017 Stock Incentive Plan (formerly known as the Company's 2008 Stock Incentive Plan). F5 · derivative.exercise_date: The remaining one-third of the restricted stock units granted to the reporting person on June 15, 2016 vested and settled for shares of the Company's common stock. F5 · derivative.expiration_date: The remaining one-third of the restricted stock units granted to the reporting person on June 15, 2016 vested and settled for shares of the Company's common stock. Read SEC document |
| June 15, 2019 Filed Jun 17, 2019 16:00 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | Exercise / conversionCommon Stock | 375 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-19-000729 · form4-06172019_040620.xml · nonDerivative · entry 3 Friedman Michael A · CIK 0001298083 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · price: The remaining one-third of the restricted stock units granted to the reporting person on June 15, 2016 vested and settled for shares of the Company's common stock. F6 · balance_after: 375 shares were transferred to the Friedman/Short Living Trust DTD 10/19/014. Read SEC document |
| June 14, 2019 Filed Jun 17, 2019 16:00 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | Exercise / conversionRestricted Stock Unit · Derivative | 300 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-19-000729 · form4-06172019_040620.xml · derivative · entry 6 Friedman Michael A · CIK 0001298083 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300 Underlying: Common Stock · 300 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: One-third of the restricted stock units granted to the reporting person on June 14, 2017 vested and settled for shares of the Company's common stock. F8 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. F11 · derivative.exercise_price: The remainder of the restricted stock units will vest as follows: 300 shares on June 14, 2020. Vested shares will be delivered to the reporting person promptly after the vesting date. F10 · price: The restricted stock units were issued pursuant to the Company's 2017 Stock Incentive Plan (formerly known as the Company's 2008 Stock Incentive Plan). F3 · derivative.exercise_date: One-third of the restricted stock units granted to the reporting person on June 14, 2017 vested and settled for shares of the Company's common stock. F3 · derivative.expiration_date: One-third of the restricted stock units granted to the reporting person on June 14, 2017 vested and settled for shares of the Company's common stock. Read SEC document |
| June 14, 2019 Filed Jun 17, 2019 16:00 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | Exercise / conversionCommon Stock | 300 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-19-000729 · form4-06172019_040620.xml · nonDerivative · entry 2 Friedman Michael A · CIK 0001298083 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: One-third of the restricted stock units granted to the reporting person on June 14, 2017 vested and settled for shares of the Company's common stock. F4 · balance_after: 300 shares were transferred to the Friedman/Short Living Trust DTD 10/19/014. Read SEC document |
| June 13, 2019 Filed Jun 17, 2019 16:00 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | Exercise / conversionRestricted Stock Unit · Derivative | 484 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-19-000729 · form4-06172019_040620.xml · derivative · entry 5 Friedman Michael A · CIK 0001298083 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 970 Underlying: Common Stock · 484 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: One-third of the restricted stock units granted to the reporting person on June 13, 2018 vested and settled for shares of the Company's common stock. F8 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. F9 · derivative.exercise_price: The remainder of the restricted stock units will vest in two annual installments as follows: 485 shares on June 13, 2020 and 485 shares on June 13, 2021. Vested shares will be delivered to the reporting person promptly after the vesting date. F10 · price: The restricted stock units were issued pursuant to the Company's 2017 Stock Incentive Plan (formerly known as the Company's 2008 Stock Incentive Plan). F1 · derivative.exercise_date: One-third of the restricted stock units granted to the reporting person on June 13, 2018 vested and settled for shares of the Company's common stock. F1 · derivative.expiration_date: One-third of the restricted stock units granted to the reporting person on June 13, 2018 vested and settled for shares of the Company's common stock. Read SEC document |
| June 13, 2019 Filed Jun 17, 2019 16:00 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | Exercise / conversionCommon Stock | 484 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-19-000729 · form4-06172019_040620.xml · nonDerivative · entry 1 Friedman Michael A · CIK 0001298083 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: One-third of the restricted stock units granted to the reporting person on June 13, 2018 vested and settled for shares of the Company's common stock. F2 · balance_after: 484 shares were transferred to the Friedman/Short Living Trust DTD 10/19/014. Read SEC document |
| June 03, 2019 Filed Jun 5, 2019 16:05 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | GrantRestricted Stock Unit · Derivative | 4,756 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-19-000666 · form4-06052019_040628.xml · derivative · entry 1 Friedman Michael A · CIK 0001298083 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,756 Underlying: Common Stock · 4,756 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. F3 · price: The restricted stock units were issued pursuant to the Company's 2017 Stock Incentive Plan. F2 · derivative.exercise_date: The restricted stock units will vest in three annual installments as follows: 1,585 shares on June 3, 2020; 1,585 shares on June 3, 2021; and 1,586 shares on June 3, 2022. Vested shares will be delivered to the reporting person promptly after the vesting date. F2 · derivative.expiration_date: The restricted stock units will vest in three annual installments as follows: 1,585 shares on June 3, 2020; 1,585 shares on June 3, 2021; and 1,586 shares on June 3, 2022. Vested shares will be delivered to the reporting person promptly after the vesting date. Read SEC document |
| May 14, 2019 Filed May 16, 2019 20:27 UTC | MANNKIND CORP MNKD · Entity 4792 | GrantRestricted Stock Unit · Derivative | 72,115 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-030386 · doc4.xml · derivative · entry 1 Friedman Michael A · CIK 0001298083 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,115 Underlying: Common Stock · 72,115 shares Expires 2029-05-14 F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of MNKD common stock. F2 · derivative.exercise_date: Annual Director Award: Restricted stock unit shall vest immediately, but the shares shall not be delivered until there is a separation of service, such as through resignation or retirement from the Board or his or her death. Read SEC document |
| April 23, 2019 Filed Apr 25, 2019 15:00 UTC | INTUITIVE SURGICAL INC ISRG · Entity 2878 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 996 | $0.00 Strike: $462.71 | $0.00 |
DisclosureSEC source: 0001035267-19-000050 · edgardoc.xml · derivative · entry 3 Friedman Michael A · CIK 0001298083 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 996 shares Expires 2028-04-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction took place in accordance with a Trading Plan that complies with SEC Rule 10b5-1 and expires on August 6, 2019. F2 · derivative.exercise_date: Non-statutory stock option granted pursuant to the Non-Employee Directors' Stock Option Plan. Option shall vest 100% one year after the date of grant or at the next Shareholders Meeting, whichever should take place first, provided that vesting will cease on termination of the Directors service to the Company. Read SEC document |
| April 23, 2019 Filed Apr 25, 2019 15:00 UTC | INTUITIVE SURGICAL INC ISRG · Entity 2878 | SaleCommon Stock | 996 | $500.00 | $498,000.00 |
DisclosureSEC source: 0001035267-19-000050 · edgardoc.xml · nonDerivative · entry 2 Friedman Michael A · CIK 0001298083 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,751 F1 · kind: This transaction took place in accordance with a Trading Plan that complies with SEC Rule 10b5-1 and expires on August 6, 2019. Read SEC document |
| April 23, 2019 Filed Apr 25, 2019 15:00 UTC | INTUITIVE SURGICAL INC ISRG · Entity 2878 | Exercise / conversionCommon Stock | 996 | $462.71 | $460,859.16 |
DisclosureSEC source: 0001035267-19-000050 · edgardoc.xml · nonDerivative · entry 1 Friedman Michael A · CIK 0001298083 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,747 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction took place in accordance with a Trading Plan that complies with SEC Rule 10b5-1 and expires on August 6, 2019. Read SEC document |
| April 19, 2019 Filed Apr 23, 2019 15:45 UTC | INTUITIVE SURGICAL INC ISRG · Entity 2878 | Exercise / conversionRestricted Stock Units · Derivative | 332 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001035267-19-000041 · edgardoc.xml · derivative · entry 2 Friedman Michael A · CIK 0001298083 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 332 shares Expires 2022-04-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The RSUs fully vest on the earlier of the first anniversary of the date of grant or the date of the next annual stockholders meeting. F2 · derivative.exercise_date: 100% of the grant will vest on the anniversary date of the grant or the next Annual Shareholders Meeting, whichever takes place first, provided however that vesting will cease on termination of the Director's service to the company. Read SEC document |
| April 19, 2019 Filed Apr 23, 2019 15:45 UTC | INTUITIVE SURGICAL INC ISRG · Entity 2878 | Exercise / conversionCommon Stock | 332 | $0.00 | $0.00 |
DisclosureSEC source: 0001035267-19-000041 · edgardoc.xml · nonDerivative · entry 1 Friedman Michael A · CIK 0001298083 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,751 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The RSUs fully vest on the earlier of the first anniversary of the date of grant or the date of the next annual stockholders meeting. Read SEC document |
| September 07, 2018 Filed Sep 10, 2018 14:48 UTC | INTUITIVE SURGICAL INC ISRG · Entity 2878 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 1,545 | $0.00 Strike: $271.48 | $0.00 |
DisclosureSEC source: 0001035267-18-000121 · edgardoc.xml · derivative · entry 6 Friedman Michael A · CIK 0001298083 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,545 shares Expires 2027-04-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction took place in accordance with a Trading Plan that complies with SEC Rule 10b5-1 and expires on August 6, 2019. F3 · derivative.exercise_date: Non-statutory stock option granted pursuant to the Non-Employee Directors' Stock Option Plan. Option shall vest 100% one year after the date of grant or at the next Shareholders Meeting, whichever should take place first, provided that vesting will cease on termination of the Directors service to the Company. Read SEC document |
| September 07, 2018 Filed Sep 10, 2018 14:48 UTC | INTUITIVE SURGICAL INC ISRG · Entity 2878 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 525 | $0.00 Strike: $185.73 | $0.00 |
DisclosureSEC source: 0001035267-18-000121 · edgardoc.xml · derivative · entry 5 Friedman Michael A · CIK 0001298083 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 525 shares Expires 2025-07-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction took place in accordance with a Trading Plan that complies with SEC Rule 10b5-1 and expires on August 6, 2019. F2 · derivative.exercise_date: Non-statutory stock option granted pursuant to the Non-Employee Directors' Stock Option Plan. Option shall vest 1/3rd one year after the date of grant and 1/36th each month thereafter. Read SEC document |
| September 07, 2018 Filed Sep 10, 2018 14:48 UTC | INTUITIVE SURGICAL INC ISRG · Entity 2878 | SaleCommon Stock | 525 | $541.46 | $284,265.87 |
DisclosureSEC source: 0001035267-18-000121 · edgardoc.xml · nonDerivative · entry 4 Friedman Michael A · CIK 0001298083 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,419 F1 · kind: This transaction took place in accordance with a Trading Plan that complies with SEC Rule 10b5-1 and expires on August 6, 2019. Read SEC document |
| September 07, 2018 Filed Sep 10, 2018 14:48 UTC | INTUITIVE SURGICAL INC ISRG · Entity 2878 | Exercise / conversionCommon Stock | 525 | $185.73 | $97,509.98 |
DisclosureSEC source: 0001035267-18-000121 · edgardoc.xml · nonDerivative · entry 3 Friedman Michael A · CIK 0001298083 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,944 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction took place in accordance with a Trading Plan that complies with SEC Rule 10b5-1 and expires on August 6, 2019. Read SEC document |
| September 07, 2018 Filed Sep 10, 2018 14:48 UTC | INTUITIVE SURGICAL INC ISRG · Entity 2878 | SaleCommon Stock | 1,545 | $541.46 | $836,553.85 |
DisclosureSEC source: 0001035267-18-000121 · edgardoc.xml · nonDerivative · entry 2 Friedman Michael A · CIK 0001298083 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,419 F1 · kind: This transaction took place in accordance with a Trading Plan that complies with SEC Rule 10b5-1 and expires on August 6, 2019. Read SEC document |
| September 07, 2018 Filed Sep 10, 2018 14:48 UTC | INTUITIVE SURGICAL INC ISRG · Entity 2878 | Exercise / conversionCommon Stock | 1,545 | $271.48 | $419,441.70 |
DisclosureSEC source: 0001035267-18-000121 · edgardoc.xml · nonDerivative · entry 1 Friedman Michael A · CIK 0001298083 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,964 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction took place in accordance with a Trading Plan that complies with SEC Rule 10b5-1 and expires on August 6, 2019. Read SEC document |
| July 23, 2018 Filed Jul 24, 2018 19:00 UTC | INTUITIVE SURGICAL INC ISRG · Entity 2878 | Exercise / conversionRestricted Stock Units · Derivative | 975 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001035267-18-000085 · edgardoc.xml · derivative · entry 2 Friedman Michael A · CIK 0001298083 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 975 shares Expires 2019-07-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 1/3 of the grant will vest on the anniversary date of the grant over a three year period, provided however that vesting will cease on termination of the Director's service to the company. Read SEC document |
| July 23, 2018 Filed Jul 24, 2018 19:00 UTC | INTUITIVE SURGICAL INC ISRG · Entity 2878 | Exercise / conversionCommon Stock | 975 | $0.00 | $0.00 |
DisclosureSEC source: 0001035267-18-000085 · edgardoc.xml · nonDerivative · entry 1 Friedman Michael A · CIK 0001298083 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,419 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These shares were acquired from the vest and release of an RSU grant previously issued to the Filer. Read SEC document |
| June 17, 2018 Filed Jun 18, 2018 16:00 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | Exercise / conversionRestricted Stock Unit · Derivative | 334 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-18-000949 · form4-06182018_040611.xml · derivative · entry 3 Friedman Michael A · CIK 0001298083 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 334 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The remaining one-third of the restricted stock units granted to the reporting person on June 17, 2015 vested and settled for shares of the Company's common stock. F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. F5 · price: The restricted stock units were issued pursuant to the Company's 2017 Stock Incentive Plan (formerly known as the Company's 2008 Stock Incentive Plan). F1 · derivative.exercise_date: The remaining one-third of the restricted stock units granted to the reporting person on June 17, 2015 vested and settled for shares of the Company's common stock. F1 · derivative.expiration_date: The remaining one-third of the restricted stock units granted to the reporting person on June 17, 2015 vested and settled for shares of the Company's common stock. Read SEC document |
| June 17, 2018 Filed Jun 18, 2018 16:00 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | Exercise / conversionCommon Stock | 334 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-18-000949 · form4-06182018_040611.xml · nonDerivative · entry 1 Friedman Michael A · CIK 0001298083 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The remaining one-third of the restricted stock units granted to the reporting person on June 17, 2015 vested and settled for shares of the Company's common stock. F2 · balance_after: 334 shares were transferred into the Friedman/Short Living Trust DTD 10/19/04. Read SEC document |
| June 15, 2018 Filed Jun 15, 2018 16:12 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | Exercise / conversionRestricted Stock Unit · Derivative | 2,038 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-18-000934 · form4-06152018_010623.xml · derivative · entry 9 Friedman Michael A · CIK 0001298083 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,038 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: All of the restricted stock units granted to the reporting person on June 15, 2011 vested and such vested restricted stock units settled for shares of the Company's common stock. F8 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. F15 · price: The restricted stock units were issued pursuant to the Company's 2017 Stock Incentive Plan (formerly known as the Company's 2008 Stock Incentive Plan). F5 · derivative.exercise_date: All of the restricted stock units granted to the reporting person on June 15, 2011 vested and such vested restricted stock units settled for shares of the Company's common stock. F5 · derivative.expiration_date: All of the restricted stock units granted to the reporting person on June 15, 2011 vested and such vested restricted stock units settled for shares of the Company's common stock. Read SEC document |
| June 15, 2018 Filed Jun 15, 2018 16:12 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | Exercise / conversionRestricted Stock Unit · Derivative | 375 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-18-000934 · form4-06152018_010623.xml · derivative · entry 8 Friedman Michael A · CIK 0001298083 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 375 Underlying: Common Stock · 375 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: One-third of the restricted stock units granted to the reporting person June 15, 2016 vested and settled for shares of the Company's common stock. F8 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. F14 · derivative.exercise_price: The remainder of the restricted stock units will vest on June 15, 2019. Vested shares will be delivered to the reporting person promptly after the vesting date. F10 · price: The restricted stock units were issued pursuant to the Company's 2017 Stock Incentive Plan. F3 · derivative.exercise_date: One-third of the restricted stock units granted to the reporting person June 15, 2016 vested and settled for shares of the Company's common stock. F3 · derivative.expiration_date: One-third of the restricted stock units granted to the reporting person June 15, 2016 vested and settled for shares of the Company's common stock. Read SEC document |
| June 15, 2018 Filed Jun 15, 2018 16:12 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | Exercise / conversionCommon Stock | 2,038 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-18-000934 · form4-06152018_010623.xml · nonDerivative · entry 3 Friedman Michael A · CIK 0001298083 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · price: All of the restricted stock units granted to the reporting person on June 15, 2011 vested and such vested restricted stock units settled for shares of the Company's common stock. F6 · balance_after: 2,038 shares were transferred into the Friedman/Short Living Trust DTD 10/19/04. Read SEC document |
| June 15, 2018 Filed Jun 15, 2018 16:12 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | Exercise / conversionCommon Stock | 375 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-18-000934 · form4-06152018_010623.xml · nonDerivative · entry 2 Friedman Michael A · CIK 0001298083 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: One-third of the restricted stock units granted to the reporting person June 15, 2016 vested and settled for shares of the Company's common stock. F4 · balance_after: 375 shares were transferred into the Friedman/Short Living Trust DTD 10/19/04. Read SEC document |
| June 14, 2018 Filed Jun 15, 2018 16:12 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | Exercise / conversionRestricted Stock Unit · Derivative | 300 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-18-000934 · form4-06152018_010623.xml · derivative · entry 7 Friedman Michael A · CIK 0001298083 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 600 Underlying: Common Stock · 300 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: One-third of the restricted stock units granted to the reporting person on June 14, 2017 vested and settled for shares of the Company's common stock. F8 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. F13 · derivative.exercise_price: The remainder of the restricted stock units will vest in two annual installments as follows: 300 shares on June 14, 2019 and 300 shares on June 14, 2020. Vested shares will be delivered to the reporting person promptly after the vesting date. F10 · price: The restricted stock units were issued pursuant to the Company's 2017 Stock Incentive Plan. F1 · derivative.exercise_date: One-third of the restricted stock units granted to the reporting person on June 14, 2017 vested and settled for shares of the Company's common stock. F1 · derivative.expiration_date: One-third of the restricted stock units granted to the reporting person on June 14, 2017 vested and settled for shares of the Company's common stock. Read SEC document |
| June 14, 2018 Filed Jun 15, 2018 16:12 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | Exercise / conversionCommon Stock | 300 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-18-000934 · form4-06152018_010623.xml · nonDerivative · entry 1 Friedman Michael A · CIK 0001298083 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: One-third of the restricted stock units granted to the reporting person on June 14, 2017 vested and settled for shares of the Company's common stock. F2 · balance_after: 300 shares were transferred into the Friedman/Short Living Trust DTD 10/19/04. Read SEC document |
| June 13, 2018 Filed Jun 15, 2018 16:12 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | GrantStock Option (right to buy) · Derivative | 13,266 | $0.00 Strike: $77.38 | $0.00 |
DisclosureSEC source: 0001415889-18-000934 · form4-06152018_010623.xml · derivative · entry 6 Friedman Michael A · CIK 0001298083 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,266 Underlying: Common Stock · 13,266 shares Expires 2028-06-13 F12 · price: The option was issued pursuant to the Company's 2017 Stock Incentive Plan. F11 · derivative.exercise_date: Option is immediately exercisable and will vest on the earlier of June 13, 2019 or the day preceding the date of the next stockholder meeting. Read SEC document |
| June 13, 2018 Filed Jun 15, 2018 16:12 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | GrantRestricted Stock Unit · Derivative | 1,454 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-18-000934 · form4-06152018_010623.xml · derivative · entry 5 Friedman Michael A · CIK 0001298083 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,454 Underlying: Common Stock · 1,454 shares Expires not disclosed F8 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. F10 · price: The restricted stock units were issued pursuant to the Company's 2017 Stock Incentive Plan. F9 · derivative.exercise_date: The restricted stock units will vest in three annual installments as follows: 484 shares on June 13, 2019; 485 shares on June 13, 2020; and 485 shares on June 13, 2021. Vested shares will be delivered to the reporting person promptly after the vesting date. F9 · derivative.expiration_date: The restricted stock units will vest in three annual installments as follows: 484 shares on June 13, 2019; 485 shares on June 13, 2020; and 485 shares on June 13, 2021. Vested shares will be delivered to the reporting person promptly after the vesting date. Read SEC document |
| May 16, 2018 Filed May 22, 2018 20:14 UTC Amendment | MANNKIND CORP MNKD · Entity 4792 | GrantRestricted Stock Unit · Derivative | 65,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-032298 · doc4a.xml · derivative · entry 1 Friedman Michael A · CIK 0001298083 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,200 Underlying: Common Stock · 65,200 shares Expires 2028-05-16 F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of MNKD common stock. F2 · date: The original Form 4 indicated the wrong transaction date of 5/18/17. The transaction date was 5/16/18. F3 · derivative.exercise_date: Restricted stock unit shall vest immediately, but the shares shall not be delivered until the director leaves the Board. Read SEC document |
| April 20, 2018 Filed Apr 20, 2018 23:01 UTC | INTUITIVE SURGICAL INC ISRG · Entity 2878 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 981 | $0.00 Strike: $213.97 | $0.00 |
DisclosureSEC source: 0001035267-18-000059 · edgardoc.xml · derivative · entry 7 Friedman Michael A · CIK 0001298083 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 981 shares Expires 2026-04-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Options will vest 100% on the earlier of the first anniversary of the date of grant or the date of the next annual stockholders meeting. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.